Signaling activated by the death receptors of the TNFR family

Biomedical Papers

Volumn 153, Issue 3, 2009, Pages 173-180

  Andera, Ladislav ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Apoptosis; Caspases; Death domain; DISC; Necroptosis

Indexed keywords

PYRONIA TITHONUS;

DEATH RECEPTOR; FAS ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL; ARTICLE; HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD95; HUMANS; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION;

EID: 70349985256     PISSN: 12138118     EISSN: 12138118     Source Type: Journal    
DOI: 10.5507/bp.2009.029     Document Type: Article

References (98)

1. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 9: 271-85
2. Locksley RM, Killeen N and Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501
3. Wilson NS, Dixit V and Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 2009; 10: 348-55
4. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72: 3666-70
5. Pennica D, Hayflick JS, Bringman TS, Palladino MA and Goeddel DV. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci U S A 1985; 82: 6060-4
6. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumournecrosis factor-alpha from cells. Nature 1997; 385: 729-33
7. Tang P, Hung MC and Klostergaard J. Human pro-tumor necrosis factor is a homotrimer. Biochemistry 1996; 35: 8216-25
8. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL and Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288: 2351-4
9. Chan FK. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 2007; 37: 101-7
10. Cottin V, Doan JE and Riches DW. Restricted localization of the TNF receptor CD120a to lipid rafts: a novel role for the death domain. J Immunol 2002; 168: 4095-102
11. Legler DF, Micheau O, Doucey MA, Tschopp J and Bron C. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. Immunity 2003; 18: 655-64
12. Fujita KI and Srinivasula SM. Ubiquitination and TNFR1 Signaling. Results Probl Cell Differ 2009;
13. Wertz IE and Dixit VM. Ubiquitin-mediated regulation of TNFR1 signaling. Cytokine Growth Factor Rev 2008; 19: 313-24
14. Lee TH, Shank J, Cusson N and Kelliher MA. The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem 2004; 279: 33185-91
15. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, et al. Both cIAP1 and cIAP2 regulate TNFalphamediated NF-kappaB activation. Proc Natl Acad Sci U S A 2008; 105: 11778-83
16. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 2008; 283: 24295-9
17. Tada K, Okazaki T, Sakon S, Kobarai T, Kurosawa K, Yamaoka S, et al. Critical roles of TRAF2 and TRAF5 in tumor necrosis factorinduced NF-kappa B activation and protection from cell death. J Biol Chem 2001; 276: 36530-4
18. Yeh WC, Shahinian A, Speiser D, Kraunus J, Billia F, Wakeham A, et al. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997; 7: 715-25
19. Ea CK, Deng L, Xia ZP, Pineda G and Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 2006; 22: 245-57
20. Wu CJ, Conze DB, Li T, Srinivasula SM and Ashwell JD. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat Cell Biol 2006; 8: 398-406
21. Blonska M, Shambharkar PB, Kobayashi M, Zhang D, Sakurai H, Su B, et al. TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation. J Biol Chem 2005; 280: 43056-63
22. Karin M and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621-63
23. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289: 2350-4
24. Shembade N, Harhaj NS, Liebl DJ and Harhaj EW. Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and LPS- mediated NF-kappaB and JNK signaling. Embo J 2007; 26: 3910-22
25. Shembade N, Harhaj NS, Parvatiyar K, Copeland NG, Jenkins NA, Matesic LE, et al. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat Immunol 2008; 9: 254-62
26. Shembade N, Parvatiyar K, Harhaj NS and Harhaj EW. The ubi- quitin-editing enzyme A20 requires RNF11 to downregulate NF- kappaB signalling. Embo J 2009; 28: 513-22
27. Habelhah H, Frew IJ, Laine A, Janes PW, Relaix F, Sassoon D, et al. Stress-induced decrease in TRAF2 stability is mediated by Siah2. Embo J 2002; 21: 5756-65
28. Nakayama K, Frew IJ, Hagensen M, Skals M, Habelhah H, Bhoumik A, et al. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell 2004; 117: 941-52
29. McDonald ER, 3rd and El-Deiry WS. Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc Natl Acad Sci U S A 2004; 101: 6170-5
30. Liao W, Xiao Q, Tchikov V, Fujita K, Yang W, Wincovitch S, et al. CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates TNF-induced NF-kappaB activation. Curr Biol 2008; 18: 641-9
31. Brummelkamp TR, Nijman SM, Dirac AM and Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003; 424: 797-801
32. Jono H, Lim JH, Chen LF, Xu H, Trompouki E, Pan ZK, et al. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. J Biol Chem 2004; 279: 36171-4
33. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D and Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801-5
34. Micheau O and Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-90
35. Wang L, Du F and Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703
36. Schutze S, Tchikov V and Schneider-Brachert W. Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat Rev Mol Cell Biol 2008; 9: 655-62
37. Festjens N, Vanden Berghe T, Cornelis S and Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007; 14: 400-10
38. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137: 1112-23
39. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313-21
40. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-9
41. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ, et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008; 135: 1311-23
42. Feng S, Yang Y, Mei Y, Ma L, Zhu DE, Hoti N, et al. Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain. Cell Signal 2007; 19: 2056-67
43. He S, Wang L, Miao L, Wang T, Du F, Zhao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009; 137: 1100-11
44. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325: 332-6
45. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-43
46. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-3
47. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. Embo J 1997; 16: 5386-97
48. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-82
49. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699-703
50. Schaefer U, Voloshanenko O, Willen D and Walczak H. TRAIL: a multifunctional cytokine. Front Biosci 2007; 12: 3813-24
51. Peter ME. The flip side of FLIP. Biochem J 2004; 382: e1-3
52. Feig C, Tchikov V, Schutze S and Peter ME. Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. Embo J 2007; 26: 221-31
53. Kohlhaas SL, Craxton A, Sun XM, Pinkoski MJ and Cohen GM. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J Biol Chem 2007; 282: 12831-41
54. Chakrabandhu K, Herincs Z, Huault S, Dost B, Peng L, Conchonaud F, et al. Palmitoylation is required for efficient Fas cell death signaling. Embo J 2007; 26: 209-20
55. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, et al. Death-receptor O-glycosylation controls tumorcell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13: 1070-7
56. Barnhart BC, Alappat EC and Peter ME. The CD95 type I/type II model. Semin Immunol 2003; 15: 185-93
57. Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC, et al. XIAP discriminates between type I and type II FAS- induced apoptosis. Nature 2009; 460: 1035-9
58. Ozoren N and El-Deiry WS. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 2002; 4: 551-7
59. Schmitz I, Walczak H, Krammer PH and Peter ME. Differences between CD95 type I and II cells detected with the CD95 ligand. Cell Death Differ 1999; 6: 821-2
60. Yin XM. Bid, a critical mediator for apoptosis induced by the activation of Fas/TNF-R1 death receptors in hepatocytes. J Mol Med 2000; 78: 203-11
61. Zha J, Weiler S, Oh KJ, Wei MC and Korsmeyer SJ. Post-translational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science 2000; 290: 1761-5
62. Billen LP, Shamas-Din A and Andrews DW. Bid: a Bax-like BH3 protein. Oncogene 2008; 27 Suppl 1: S93-104
63. Ott M, Norberg E, Zhivotovsky B and Orrenius S. Mitochondrial targeting of tBid/Bax: a role for the TOM complex? Cell Death Differ 2009; 16: 1075-82
64. Roucou X, Montessuit S, Antonsson B and Martinou JC. Bax oligomerization in mitochondrial membranes requires tBid (caspase- 8-cleaved Bid) and a mitochondrial protein. Biochem J 2002; 368: 915-21
65. Schafer B, Quispe J, Choudhary V, Chipuk JE, Ajero TG, Du H, et al. Mitochondrial outer membrane proteins assist Bid in Bax- mediated lipidic pore formation. Mol Biol Cell 2009; 20: 2276-85
66. Kroemer G, Galluzzi L and Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163
67. Gonzalvez F, Schug ZT, Houtkooper RH, MacKenzie ED, Brooks DG, Wanders RJ, et al. Cardiolipin provides an essential activating platform for caspase-8 on mitochondria. J Cell Biol 2008; 183: 681-96
68. Falschlehner C, Schaefer U and Walczak H. Following TRAIL's path in the immune system. Immunology 2009; 127: 145-54
69. Strasser A, Jost PJ and Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009; 30: 180-92
70. Bouillet P and O'Reilly LA. CD95, BIM and T cell homeostasis. Nat Rev Immunol 2009; 9: 514-9
71. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008; 118: 100-10
72. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005; 434: 88-93
73. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489-95
74. Strauss G, Lindquist JA, Arhel N, Felder E, Karl S, Haas TL, et al. CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. J Exp Med 2009; 206: 1379-93
75. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-63
76. Bellail AC, Qi L, Mulligan P, Chhabra V and Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 2009; 4: 34-41
77. Papenfuss K, Cordier SM and Walczak H. Death receptors as targets for anti-cancer therapy. J Cell Mol Med 2008; 12: 2566-85
78. Headon DJ and Overbeek PA. Involvement of a novel Tnf receptor homologue in hair follicle induction. Nat Genet 1999; 22: 370-4
79. Gaide O and Schneider P. Permanent correction of an inherited ectodermal dysplasia with recombinant EDA. Nat Med 2003; 9: 614-8
80. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A and Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424: 793-6
81. Yan M, Zhang Z, Brady JR, Schilbach S, Fairbrother WJ and Dixit VM. Identification of a novel death domain-containing adaptor molecule for ectodysplasin-A receptor that is mutated in crinkled mice. Curr Biol 2002; 12: 409-13
82. Chen Y, Zeng J, Chen Y, Wang X, Yao G, Wang W, et al. Multiple roles of the p75 neurotrophin receptor in the nervous system. J Int Med Res 2009; 37: 281-8
83. Teng KK and Hempstead BL. Neurotrophins and their receptors: signaling trios in complex biological systems. Cell Mol Life Sci 2004; 61: 35-48
84. Casaccia-Bonnefil P, Carter BD, Dobrowsky RT and Chao MV. Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Nature 1996; 383: 716-9
85. Volosin M, Trotter C, Cragnolini A, Kenchappa RS, Light M, Hempstead BL, et al. Induction of proneurotrophins and activation of p75NTR-mediated apoptosis via neurotrophin receptor-interacting factor in hippocampal neurons after seizures. J Neurosci 2008; 28: 9870-9
86. Chinnaiyan AM, O'Rourke K, Yu GL, Lyons RH, Garg M, Duan DR, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996; 274: 990-2
87. Pan G, Bauer JH, Haridas V, Wang S, Liu D, Yu G, et al. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett 1998; 431: 351-6
88. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002; 16: 479-92
89. Fang L, Adkins B, Deyev V and Podack ER. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med 2008; 205: 1037-48
90. Meylan F, Davidson TS, Kahle E, Kinder M, Acharya K, Jankovic D, et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 2008; 29: 79-89
91. Al-Lamki RS, Wang J, Tolkovsky AM, Bradley JA, Griffin JL, Thiru S, et al. TL1A both promotes and protects from renal inflammation and injury. J Am Soc Nephrol 2008; 19: 953-60
92. Bull MJ, Williams AS, Mecklenburgh Z, Calder CJ, Twohig JP, Elford C, et al. The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. J Exp Med 2008; 205: 2457-64
93. Klima M, Zajedova J, Doubravska L and Andera L. Functional analysis of the posttranslational modifications of the Death Receptor 6. Biochim Biophys Acta 2009;
94. Liu J, Heuer JG, Na S, Galbreath E, Zhang T, Yang DD, et al. Accelerated onset and increased severity of acute graft-versus-host disease following adoptive transfer of DR6-deficient T cells. J Immunol 2002; 169: 3993-8
95. Liu J, Na S, Glasebrook A, Fox N, Solenberg PJ, Zhang Q, et al. Enhanced CD4+ T cell proliferation and Th2 cytokine production in DR6-deficient mice. Immunity 2001; 15: 23-34
96. Schmidt CS, Liu J, Zhang T, Song HY, Sandusky G, Mintze K, et al. Enhanced B cell expansion, survival, and humoral responses by targeting death receptor 6. J Exp Med 2003; 197: 51-62
97. Zhao H, Yan M, Wang H, Erickson S, Grewal IS and Dixit VM. Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice. J Exp Med 2001; 194: 1441-8
98. Nikolaev A, McLaughlin T, O'Leary DD and Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009; 457: 981-9